Astrocytoma, IDH-Mutant, Grade 3 — Trials

Astrocytoma, IDH-Mutant, Grade 3 — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 5
Ph III recruiting: 2
Growth YoY: —
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06860594	Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 2, 2026	clinicaltrials
NCT07215910	Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer	recruiting	Phase 3	408	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026